Skip to main content

Advertisement

SpringerLink
Log in

Prolymphocytic leukemia

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Prolymphocytic leukemia is a rare chronic lymphoproliferative disorder that includes two subtypes, B cell and T cell, each with its own distinct clinical, laboratory and pathological features. T-cell prolymphocytic leukemia has an aggressive course with short median survival and poor response to chemotherapy. With the use of the purine analogue pentostatin more than half of patients will have a major response and a minority will have a complete remission, usually lasting months. With the introduction of alemtuzumab, most patients who progressed despite treatment with pentostatin had a major response with a complete remission rate higher than that obtained with pentostatin when used as a first line. Unfortunately, progression still follows shortly. We recommend alemtuzumab as initial therapy and offer stem cell transplant (SCT) to selected young, healthy patients who respond. Although B-cell prolymphocytic leukemia is also a progressive disease, some patients can achieve a prolonged progressionfree-survival with fludarabine. Patients presenting with massive splenomegaly may be effectively palliated with splenic irradiation or splenectomy. Rituximab is a promising agent and further investigations are warranted to better define its role in treatment of this disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Matutes E, Brito-Babapulle V, Swansbury J, et al.: Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991, 78:3269–3274. This case series is one of the largest for T-PLL and provides a useful overview of the usual clinical manifestations and prognosis of T-PLL.

    PubMed  CAS  Google Scholar 

  2. Pawson R, Schulz TF, Matutes E, et al.: The human T-cell lymphotropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia. Leukemia 1997, 11:1305–1311.

    Article  PubMed  CAS  Google Scholar 

  3. Brito-Babapulle V, Maljaie SH, Matutes E, et al.: Relationship of T leukaemias with cerebriform nuclei to T-prolymphocytic leukaemia: a cytogenetic analysis with in situ hybridization. Br J of Haematol 1997, 96:724–732.

    Article  CAS  Google Scholar 

  4. Jaffe ES, Harris NL, Stein H, Vardiman JW: Pathology and Genetics of Tumours of Haematopoietic and Lympkoid Tissues. World Health Organization Classification of Tumours; IARC Press, 2001.

  5. Ginaldi L, De Martinis M, Matutes E, et al.: Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998, 22:185–191.

    Article  PubMed  CAS  Google Scholar 

  6. Virgilio L, Lazzeri C, Bichi R, et al.: Deregulated expression of TCL1 causes T-cell leukemia in mice. Proc Natl Acad Sci 1998, 95:3885–3889.

    Article  PubMed  CAS  Google Scholar 

  7. Pekarsky Y, Hallas C, Isobe M, et al.: Abnormalities at 14q32.1 in T-cell malignancies involve two oncogenes. Proc Natl Acad Sci 1999, 96:2949–2951.

    Article  PubMed  CAS  Google Scholar 

  8. Stilgenbauer S, Schaffner C, Litterst A, et al.: Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 1997, 3:1155–1159.

    Article  PubMed  CAS  Google Scholar 

  9. Shvidel L, Shtalrid M, Bassous L, et al.: B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors, and evidence for a group with an indolent course. Leuk Lymphoma 1999, 33:169–179. This case series, along with the one reported by Hercher et al. [10 ], establishes the usual clinical manifestation, diversity, and prognosis of B-PLL.

    PubMed  CAS  Google Scholar 

  10. Hercher C, Robain M, Davi F, et al.: A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. Leuk Lymphoma 2001. 42(5): pp. 981–987. This case series, along with the one reported by Shvidel et al. [9 ], establishes the usual clinical manifestation, diversity, and prognosis of B-PLL.

    Article  PubMed  CAS  Google Scholar 

  11. Matutes E, Owusu-Ankomah K, Morilla R, et al.: The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994, 8:1640–1645.

    PubMed  CAS  Google Scholar 

  12. Schlette E, Bueso-Ramos C, Giles F, et al.: Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol 2001, 115:571–581.

    Article  PubMed  CAS  Google Scholar 

  13. Brito-Babapulle V, Pittman S, Melo JV, et al.: Cytogenetic studies on prolymphocytic leukemia. B-cell prolymphocytic leukemia. Hem Pathol 1987, 1:27–33.

    CAS  Google Scholar 

  14. Brito-Babapulle V, Catovsky D, et al.: Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genet Cytogenet 1991, 55:1–9.

    Article  PubMed  CAS  Google Scholar 

  15. Wong KF, Chan JK, Sin VC, et al.: T-cell form of chronic lymphocytic leukaemia: a reaffirmation of its existence. Br J Haematol 1996, 93:157–159.

    Article  PubMed  CAS  Google Scholar 

  16. Cavazzini F, Cuneo A, Bardi A, et al.: Indolent T-cell prolymphocytic leukemia: a case report and a review of the literature. Am J Hematol 2003, 74:145–147.

    Article  PubMed  Google Scholar 

  17. Catovsky D, Matutes E, Brito-Babapulle V, et al.: Is T-cell CLL a disease entity? Br J Haematol 1996, 94:580.

    PubMed  CAS  Google Scholar 

  18. Garand R, Goasguen J, Brizard A, et al.: Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Br J Haematol 1998, 103:488–494.

    Article  PubMed  CAS  Google Scholar 

  19. Robertson LE, Keating MJ, et al.: Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions. Cancer Treat Res 1993, 64:105–119.

    PubMed  CAS  Google Scholar 

  20. Saven A, Lemon RH, Kosty M, et al.: 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995, 13:570–574.

    PubMed  CAS  Google Scholar 

  21. Rondelli D, Lauria F, Zinzani PL, et al.: 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders. Eur J Haematol 1997, 58:46–50.

    Article  PubMed  CAS  Google Scholar 

  22. Barton K, Larson RA, O’Brien S, et al.: Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine. J Clin Oncol 1992, 10:1821.

    PubMed  CAS  Google Scholar 

  23. Palomera L, Domingo JM, Agullo JA, et al.: Complete remission in T-cell prolymphocytic leukemia with 2-chlorodeoxyadenosine. J Clin Oncol 1995, 13:1284–1285.

    PubMed  CAS  Google Scholar 

  24. Lorand-Metze I, Oliveira GB, Aranha FJ: Treatment of prolymphocytic leukemia with cladribine. Ann Hematol 1998, 76:85–86.

    Article  PubMed  CAS  Google Scholar 

  25. Mercieca J, Matutes E, Dearden C, et al.: The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994, 12:2588–2593.

    PubMed  CAS  Google Scholar 

  26. Van Den Neste E, Delannoy A, Vandercam B, et al.:Infectious complications after 2-chlorodeoxyadenosine therapy. Eur J Haematol 1996, 56:235–240.

    Article  Google Scholar 

  27. Treumann A, Lifely MR, Schneider P, et al.: Primary structure of CD52. J Biol Chemist 1995, 270:6088–6099.

    Article  CAS  Google Scholar 

  28. Bowen AL, Zomas A, Emmett E, et al.: Subcutaneous Campath-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 1997, 96:617–619.

    Article  PubMed  CAS  Google Scholar 

  29. Pawson R, Dyer MJ, Barge R, et al.: Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997, 15:2667–2672. This study is the first large phase II study conducted by the European collaborative group investigating alemtuzumab in 15 patients with T-PLL who had either progressive or refractory disease despite previous treatment, and compared the results with a matched group of patients who received pentostatin.

    PubMed  CAS  Google Scholar 

  30. Dearden CE, Matutes E, Cazin B, et al.: High-remission rate in T-cell prolymphocytic leukemia with Campath-1H. Blood, 2001, 98:1721–1726. This study reported the results of 39 patients with relapsed/ refractory T-PLL who received alemtuzumab, some of whom had received a subsequent SCT.

    Article  PubMed  CAS  Google Scholar 

  31. Keating MJ, Cazin B, Coutre S, et al.: Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002, 20:205–213. This is the largest study for using alemtuzumab in relapsed/ refractory T-PLL that established the role of alemtuzumab in T-PLL.

    Article  PubMed  CAS  Google Scholar 

  32. Cheson BD, Bennett JM, Grever M, et al.: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87:4990–4997.

    PubMed  CAS  Google Scholar 

  33. Lundin J, Kimby E, Bjorkholm M, et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100:768–773.

    Article  PubMed  CAS  Google Scholar 

  34. Keating M, Coutre S, Rai K, et al.: Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004, 4:220–227. This is an important review for the guidelines of using alemtuzumab in CLL, the same applied when used for T-PLL.

    PubMed  CAS  Google Scholar 

  35. Nguyen DD, Cao TM, Dugan K, et al.: Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 2002, 3:105–110.

    Article  PubMed  CAS  Google Scholar 

  36. Aggio MC: Splenic irradiation as initial therapy for prolymphocytic leukemia. Eur J Haematol 1992, 49:46–47.

    Article  PubMed  CAS  Google Scholar 

  37. Yamamoto K, Hamaguchi H, Nagata K, et al.: Splenic irradiation for prolymphocytic leukemia: is it preferable as an initial treatment or not? Jap J Clin Oncol 1998, 28:267–269.

    Article  CAS  Google Scholar 

  38. Saven A, Lee T, Schlutz M, et al.: Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. J Clin Oncol 1997, 15:37–43.

    PubMed  CAS  Google Scholar 

  39. Montillo M, Tedeschi A, O’Brien S, et al.: Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003, 97:114–120.

    Article  PubMed  CAS  Google Scholar 

  40. Chun HG, Leyland-Jones B, Cheson BD: Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 1991, 9:175–188.

    PubMed  CAS  Google Scholar 

  41. Kantarjian HM, Redman JR, Keating MJ: Fludarabine phosphate therapy in other lymphoid malignancies. Semin Oncol 1990, 17(Suppl8):66–70.

    PubMed  CAS  Google Scholar 

  42. Marlton P, McCarthy C, Taylor K: Fludarabine-induced cytogenetic remission in prolymphocytic leukemia. Am J Hematol 1992, 40:71–72.

    Article  PubMed  CAS  Google Scholar 

  43. Reff ME, Carner K, Chinn PC, et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435–445.

    PubMed  CAS  Google Scholar 

  44. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: 50% of patients respond to a four dose treatment program. J Clin Oncol 1998, 16:2825–2833.

    PubMed  CAS  Google Scholar 

  45. Czuczman MS: Combination chemotherapy and rituximab. Anti-Cancer Drugs 2001, 12(Suppl 2):S15-S19.

    PubMed  CAS  Google Scholar 

  46. Mourad YA, Taher A, Chehal A, et al.: Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody. Ann Hematol 2004, 83:319–321.

    Article  PubMed  Google Scholar 

  47. Vartholomatos G, Tsiara S, Christou L, et al.: Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia. Acta Haematol 1999, 102:94–98.

    Article  PubMed  CAS  Google Scholar 

  48. Perz J, Topaly J, Fruehauf S, et al.: Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2002, 43:149–151.

    Article  PubMed  CAS  Google Scholar 

  49. Shvidel L, Shtalrid M, Klepfish A, et al.: Successful autologous stem cell transplantation in aggressive prolymphocytic leukemia. Am J Hematol 2000, 63:230–231.

    Article  PubMed  CAS  Google Scholar 

  50. Mehta J, Powles R, Singhal S, et al.: Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versushost disease: possible role of graft-versus-leukemia. Bone Marrow Transplant 1996, 17:371–375.

    PubMed  CAS  Google Scholar 

  51. Frankel AE, Fleming DR, Hall PD, et al.: A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res 2003, 9:3555–3561.

    PubMed  CAS  Google Scholar 

  52. Olsen E, Duvic M, Frankel A, et al.: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001, 19:376–388.

    PubMed  CAS  Google Scholar 

  53. Murase K, Matsunaga T, Sato T, et al.: Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement. Int J Clin Oncol 2003, 8:391–394.

    Article  PubMed  Google Scholar 

  54. Garderet L, Bittencourt H, Kaliski A, et al.: Treatment of T-prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation. Eur J Haematol 2001, 66:137–139.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Taussig Cancer Cancer, The Cleveland Clinic Foundation, 9500 Euclid Avenue R35, 44195, Cleveland, OH, USA

    Matt Kalaycio MD

Authors
  1. Ahmed Absi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Hsi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matt Kalaycio MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Absi, A., Hsi, E. & Kalaycio, M. Prolymphocytic leukemia. Curr. Treat. Options in Oncol. 6, 197–208 (2005). https://doi.org/10.1007/s11864-005-0003-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-005-0003-4

Keywords

Search

Navigation